Novo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the ...

Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics and its potential rival to Novartis’ Rhapsido. The all-stock deal will secure Processa an ...

AbCellera’s T-cell engager (TCE) platform has reeled in a second client this summer, with Vertex Pharmaceuticals ...

Caldera Therapeutics has struck a reverse merger with the Nasdaq-listed Synlogic and inked a $278 million financing deal, ...

GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research ...

Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural ...

An experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial providing hope ...

Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements. | Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare ...

Medical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally. This takes shape in the form of a newly agreed ...

Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate (ADC) to another phase 3 win in ...

A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.  | A new biotech has come into view with a $118 million series B and a vision ...

Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance ...